title: TLR2 and TLR4 expression after kidney ischemia and reperfusion injury in mice treated with FTY720.
abstract: Ischemia and reperfusion injury (IR) is an antigen independent inflammatory process that causes tissue damage. After IR, kidneys up-regulate leukocyte adhesion molecules and toll-like receptors (TLRs). Moreover, injured kidneys can also secrete factors (i.e. heat shock protein) which bind to TLRs and trigger intracellular events culminating with the increase in the gene expression of inflammatory cytokines. FTY720 is an immunomodulatory compound and protects at least in part kidneys submitted to IR. The mechanisms associated with FTY720's beneficial effects on kidneys after IR remain elusive. We investigated whether FTY720 administration in mice submitted to kidney IR is associated with modulation of TLR2 and TLR4 expression. C57BL/6 mice submitted to 30min of renal pedicles clamp were evaluated for serum parameters (creatinine, urea and nitric oxide), kidney histology, spleen and kidney infiltrating cells expression of TLR2 and TLR4, resident kidney cells expression of TLR2 and TLR4 and IL-6 protein expression in kidney. FTY720-treated mice presented decrease in serum creatinine, urea and nitric oxide, diminished expression of TLR2 and TLR4 both in spleen and kidney infiltrating cells, and reduced kidney IL-6 protein expression in comparison with IR non-treated mice. However, acute tubular necrosis was present both in IR non-treated and IR+FTY720-treated groups. Also, FTY720 did not prevent TLR2 and TLR4 expression in kidney resident cells. In conclusion, FTY720 can promote kidney function recovery after IR by reducing the inflammatory process. Further studies are needed in order to establish whether TLR2 and TLR4 down regulation should be therapeutically addressed as protective targets of renal function and structure after IR.
authors.affiliation: Nephrology Division, UNIFESP Federal University of São Paulo, São Paulo, Brazil.
authors.forename: J F
authors.initials: JF
authors.lastname: Pedregosa
authors.forename: A A
authors.initials: AA
authors.lastname: Haidar
authors.forename: A E
authors.initials: AE
authors.lastname: Hirata
authors.forename: M
authors.initials: M
authors.lastname: Franco
authors.forename: G N
authors.initials: GN
authors.lastname: Gomes
authors.forename: V
authors.initials: V
authors.lastname: Bueno
mesh_terms: D000818:Animals; D003404:Creatinine / Q000097:blood; D000068876:Fingolimod Hydrochloride; D015850:Interleukin-6 / Q000235:genetics / Q000378:metabolism; D007668:Kidney / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D009569:Nitric Oxide / Q000097:blood; D011409:Propylene Glycols / Q000494:pharmacology*; D015427:Reperfusion Injury / Q000235:genetics* / Q000378:metabolism* / Q000473:pathology / Q000517:prevention & control; D013110:Sphingosine / Q000031:analogs & derivatives* / Q000494:pharmacology; D013154:Spleen / Q000187:drug effects / Q000378:metabolism; D051195:Toll-Like Receptor 2 / Q000037:antagonists & inhibitors / Q000096:biosynthesis* / Q000235:genetics* / Q000378:metabolism; D051197:Toll-Like Receptor 4 / Q000037:antagonists & inhibitors / Q000096:biosynthesis* / Q000235:genetics* / Q000378:metabolism; D014508:Urea / Q000097:blood; D000093242:Interleukin-6 Inhibitors
chemical_list: D003404:Creatinine; D000068876:Fingolimod Hydrochloride; D015850:Interleukin-6; D009569:Nitric Oxide; D011409:Propylene Glycols; D013110:Sphingosine; D051195:Toll-Like Receptor 2; D051197:Toll-Like Receptor 4; D014508:Urea; D000093242:Interleukin-6 Inhibitors; C493486:Tlr2 protein, mouse; C493487:Tlr4 protein, mouse